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Abstract Osteonecrosis (ON) in the knee occurs as a
localized inflammatory disease in relation to spontaneous
or non-traumatic ON. Conservative treatment possibilities
are limited, and prognosis appears to be poor; in most
cases, ON results in knee arthroplasty. Bisphosphonates are
suggested to prevent bone resorption and collapse of
necrotic bone. In this observational, prospective study we
investigated the effect of bisphosphonate treatment in
patients with spontaneous or arthroscopy-induced ON of
the knee. Twenty-eight patients with osteonecrotic lesions
and bone marrow oedema in the knee were included. In 22
patients (80%), ON was identified after arthroscopic sur-
gery of the knee; six patients were diagnosed with spon-
taneous ON. Patients were initially given pamidronate
120 mg i.v. divided in 3–4 perfusions over 2 weeks, fol-
lowed by oral bisphosphonate treatment with alendronate
70 mg weekly for 4–6 months. Bisphosphonate treatment
resulted in a rapid pain relief, VAS decreasing from
8.2 ± 1.2 at baseline to 5.02 ± 0.6 after 4–6 weeks
(p \ 0.001). After 6 months, the VAS decreased by 80%
(p \ 0.001). At the 6-month follow-up, symptoms had
resolved completely in 15 patients out of 28; in 6 patients,
minimal symptoms (VAS 1–2) remained. In two patients,
treatment effect was unsatisfactory, and surgical interven-
tion was needed (arthroplasty). Bone marrow oedema on
MRI resolved completely in 18 patients out of 28 with
substantial reduction in the remaining. Furthermore, oste-
onecrotic area resolved completely or demarcation with
sclerotic changes of the necrotic area could be observed.
Bisphosphonate treatment in patients with osteonecrosis
of the knee was associated with a rapid improvement in
pain score and radiological consolidation of the area of
osteonecrosis. Further randomized, controlled trials are
warranted to confirm the potential beneficial role of
bisphosphonates in the treatment of osteonecrosis of the
knee. Level of evidence: observational study, level IV.
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Introduction
Osteonecrosis (ON) is a localized inflammatory disease
primarily affecting bone tissue. In its early stage, the
overlaying articular cartilage is intact; however, with pro-
gression of the disease, structural failure in subchondral
bone and overlaying cartilage tissue occurs [4, 7, 32, 40,
51]. Osteonecrosis of the knee is generally classified into
two groups based on their underlying pathophysiological
mechanisms [7, 15, 24, 40]. Spontaneous osteonecrosis of
the knee (SONK) is characterized by a sudden onset of
knee pain and affects predominately postmenopausal
women [24, 40]. Although many causes have been pro-
posed, the exact aetiology of ON of the knee is not entirely
elucidated [17, 35, 39, 42, 46]. Primary or secondary vas-
cular insufficiency leading to infarction of bone and minor,
unrecognized traumatic incidents producing microfractures
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in the subchondral bone have been proposed [17, 35, 39,
42, 46]. Currently, the mechanical theory is favoured lar-
gely based on the finding of meniscal tears at the site of
osteonecrotic condyle lesions. Histopathological studies
support the theory of subchondral insufficiency fractures
[23, 34, 38, 52]. The second type of osteonecrosis, sec-
ondary or atraumatic osteonecrosis, is in most cases related
to medical conditions such as corticosteroid treatment,
sickle cell anaemia, systemic lupus erythematosus, hyper-
barism and alcohol abuse [24, 40]. The onset of pain is
rather gradual, and the disease occurs usually in patients
under 50 years of age, predominantly women. In most
cases, other joints are also involved, bilateral affection is
very common. Similar to avascular necrosis of the hip, the
underlying cause seems to be systemic and mostly of
vascular origin.
Osteonecrosis of the knee after arthroscopy is a rela-
tively new diagnostic entity and has been described in
several reports [6, 10, 12, 13, 20, 23, 26, 35, 39, 42, 46]. In
49 cases, in which ON has been reported after arthroscopy,
the development of osteonecrosis was diagnosed secondary
to treatment of meniscal and chondral lesions or recon-
struction of an intraarticular ligament. In some, bone
lesions were thought to be in direct relation with meniscal
or chondral lesions [10, 13, 15, 20, 26, 35, 39, 42, 46]. The
prognosis of ON after arthroscopic surgery remains unclear
but appears to be poorer than in ordinary SONK resulting
in knee arthroplasty in many cases. Furthermore, conser-
vative treatment options are limited and mostly already
exhausted.
Bisphosphonates inhibit bone resorption and are widely
used in metabolic bone disease characterized by increased
osteoclast activity (i.e. osteoporosis, Paget’s disease) [45].
In ON, structural failure is the result of resorption of
necrotic bone during revascularisation, before new bone
has formed. It can be hypothesized that if accelerated bone
resorption could be reduced during the revascularization
process until sufficient new bone has been formed, it
would appear that structural failure with subsequent
osteoarthritis could be avoided. In animal studies, it has
been shown that bisphosphonate treatment prevents
resorption of necrotic bone during revascularization and
bone deformity [8, 9, 27, 30]. In humans, bisphosphonate
treatment has been used successfully in bone marrow
oedema and avascular necrosis of the femoral head [3, 28,
29, 44, 49]. In these reports, the use of bisphosphonates
was followed by a rapid improvement of clinical symp-
toms and radiological findings. To date, there is no report
on the use of bisphosphonate treatment in ON of the knee.
This observational, prospective study summarizes the
effect of bisphosphonate treatment on the clinical and
radiological course in patients with spontaneous or
postarthroscopic ON of the knee.
Materials and methods
Study population
Twenty-eight patients with the radiologic finding of
osteonecrotic lesions and bone marrow oedema in the
knee were recruited into this open-label, prospective
observational study. In 22 patients (80%), ON was iden-
tified after arthroscopic surgery of the knee. Six patients
were diagnosed with spontaneous osteonecrosis of the
knee (SONK).
All patients included in the study had to be symptomatic
and to meet the MRI diagnostic criteria. The criteria for
diagnosis of ON on MRI included normal high-intensity
signal of fat in the bone marrow replaced by a discrete low-
intensity signal in the centre of the lesion and high-inten-
sity signal area about the margin representing bone marrow
oedema (Fig. 1). The size of the lesion was measured on
T1-weighted images as the area of low signal intensity
as described by Lotke et al. [32]. Informed consent to
participate in the study was obtained from all patients,
according to the rules of the local ethics committee.
Intervention
Patients were initially given pamidronate 120 mg i.v.
divided in 3–4 perfusions over 2 weeks, followed by oral
bisphosphonate treatment with alendronate 70 mg weekly
for 4–6 months. This treatment regimen was chosen in
analogy to experimental animal studies in which resorp-
tion of necrotic bone with alendronate treatment was
prevented by doses 4–50 times higher than the dose used
in patients with osteoporosis. It was felt that an IV
loading with bisphosphonate would therefore be more
effective [8].
All patients were given non-steroidal anti-inflammatory
or analgesics as needed. Weight-bearing was not forbidden
but was usually avoided by the patients because of pain.
Calcium (500–1,000 mg/day) and vitamin D (400–
800 IU/day) supplements were provided throughout the
whole treatment period.
Measurements
The initial evaluation included magnetic resonance imag-
ing (MRI) in all patients and radiographs in a subset of
patients, as well as a clinical and laboratory assessment.
Clinical assessments were made before treatment,
1 month later and thereafter at 6–12 weeks intervals. A
further MRI scan was performed 3 months after initiating
treatment.
Blood and urine samples were taken in the morning after
an overnight fast. The baseline laboratory assessment
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included c-reactive protein, complete blood count, serum
calcium, liver- and kidney function parameters, glucose,
haemoglobin A1c and screening for coagulopathies.
Calcium, creatinine and total alkaline phosphatase
(ALP) were analysed by standard method on an autoana-
lyser (Hitachi System 704 analyser; Roche Diagnostics,
Rotkreuz, Switzerland). Serum bone alkaline phosphatise
(BAP) concentration was determined by ELISA (ALK-
PHASE-B ELISA, Quidel) [22]. The parameters N-MID-
Osteocalcin (OC) and intact parathyroid hormone (PTH)
were measured in serum with electrochemiluminescence
immunoassays (ECLIA) on the automated analyser Elecsys
2010 (Roche Diagnostics, Rotkreuz/Switzerland) [21, 47].
The intra- and interassay variation was 1.1–5.9% for OC,
2.6–6 and 1.7–5.5% for intact PTH. Urinary C-terminal
teleopeptides of type I collagen was determined by ELISA
(Nordic Bioscience Diagnostics A/S, Denmark) and cor-
rected for creatinine [18]. The intra- and interassay CV’s
were 3.5 and 8.6%, respectively. Pyridinium collagen
cross-links (pyridinoline [PYD] and deoxypyridinoline
[DPD]) were measured by high performance liquid chro-
matography (HPLC) using a commercially available kit
from Chromsystems Instruments and Chemicals, Munich
(Germany), and the results were expressed in relation to the
urinary creatinine. The intra- and interassay were 8.3 and
11.5%, respectively.
Pain was measured at baseline and during follow-up
using a standardized visual analogue scale (VAS) [25].
Statistical analysis
All data are expressed as means ± standard errors of the
mean (SEM). To compare study variables during study
period, one-way ANOVA for repeated measures with post
hoc comparisons corrected for multiple testing by least
squares difference (LSD) was used. Significance was
defined as p \ 0.05. Data were analysed using Statistica for
Windows (version 6.0; StatSoft, Tulsa, OK, USA).
Results
Baseline characteristics
The baseline characteristics are summarized in Table 1.
Twenty-two patients had an arthroscopy for meniscal
lesions or osteoarthritis, and in six patients, ON developed
spontaneously. The median time interval between arthros-
copy or occurence of symptoms (in patients with SONK)
and inclusion into the study was 4.0 months (range,
3 weeks to 24 months).
Laboratory investigations
Baseline laboratory investigations did not reveal any spe-
cific risk factor or disease associated with ON (Table 1).
Bisphosphonate treatment resulted in an inhibition of bone
Fig. 1 X-ray (a) and magnetic resonance image (b) of a 62-year-old female patient from the series showing typical ostenecrotic lesion and
oedema of the femoral condyle
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turnover, as evidenced by a significant decrease in urinary
levels of CTx, PYD and DPD (already after 4 weeks) and a
decrease in serum concentrations of OC, TALP and BAP
(after 3 months; Table 2).
Pain and disability
The mean VAS at baseline was 8.2 ± 1.2. As expected
with such high VAS pain scores, quality of life and walking
ability was severely reduced. Mobility was also affected,
and patients could not walk a longer distance without
walking aid.
Bisphosphonate treatment resulted in a rapid and sub-
stantial pain relief (Fig. 2). After 6 months of bisphospho-
nate therapy, the VAS decreased by 80% in average, and
all patients achieved a reduction of at least 50–60%. At the
6-months follow-up in 15 patients out of 27 symptoms had
resolved completely and in 6 patients complained of min-
imal residual pain (VAS 1–2). At 1 year follow-up, clinical
data on 18 patients were available, and VAS was still
reduced significantly (2.2 ± 0.8, p \ 0.001), 14 patients
reported to be free of symptoms. In 1 patient, there was
evidence of moderate impression of the articular surface of
the femoral condyle, however, as the patient was asymp-
tomatic in his daily activities and in exercising (jogging)
conservative treatment was continued. In two patients,
treatment effect was unsatisfactory and surgical interven-
tion (alloarthroplasty) was necessary.
Although no quantitative assessment of functional dis-
ability was performed, improvement in quality of life was
apparent from the resolution of pain and considerable
improvement in mobility was evident. All but two patients
showed improvement in their walking ability without the
needed of a walking aid.
Table 1 Baseline characteristics
Normal range Results
Age (years) 57.7 ± 2.7
Height (cm) 164.6 ± 2.1
Weight (kg) 75.7 ± 3.3
Serum
Calcium (mmol/l) 2.15–2.62 2.43 ± 0.02
Creatinine (lmol/l) \97 73.4 ± 3.2
Total ALP (U/L) 35–104 79.3 ± 5.2
Bone ALP (lg/l) 7.4–15.7 13.8 ± 2.1
Osteocalcin (ng/ml) 7.7–32 21.5 ± 1.9
Intact PTH (pg/ml) 10–60 36.2 ± 5.8
25-OH Vitamin D (ng/ml) [25 18.7 ± 3.6
Glucose (fasting) (mmol/l) \6.1 5.3 ± 0.6
HbA1c (%) \5.7 5.1 ± 0.7
Urine
Calcium/creatinine (mmol/mmol) 0.1–0.32 0.25 ± 0.04
PYD/creatinine (mmol/mmol) 60–100 97.3 ± 12.7*
DPD/creatinine (nmol/mmol) 9–20 19.1 ± 2.4*
CTx/creatinine (lg/mmol) 80–320 281.6 ± 38*
Mean ± SEM/*p \ 0.05 compared to age-matched controls
Table 2 Biochemical parameters during follow-up
Baseline 1 Month 3 Months 6 Months
Calcium (mmol/l) 2.44 ± 0.02 2.39 ± 0.02 2.35 ± 0.04 2.46 ± 0.03
Creatinine (lmol/l) 73.4 ± 3.3 75.2 ± 3.4 78.1 ± 5.7 81.9 ± 6.3
ALP (U/L) 79.3 ± 5.3 78.1 ± 7.2 80.8 ± 11.0 64.8 ± 4.5*
OC (ng/ml) 21.5 ± 2.0 18.9 ± 2.3 12.5 ± 1.7* 14.5 ± 2.3*
PYD (nM/mM creatinine) 97.3 ± 12.7 59.4 ± 13.0* 44.9 ± 4.2* 54.4 ± 4.4*
DPD (nM/mM creatinine) 19.0 ± 2.4 10.6 ± 2.4* 8.2 ± 0.7* 9.7 ± 0.9*
CTx (lg/mM creatinine) 231.6 ± 38.5 40.4 ± 14.0* 52.3 ± 14.7* 75.3 ± 15.0*
ALP total alkaline phosphatase; OC osteocalcin; PYD pyridinoline; DPD deoxypyridinoline; CTx c-terminal telopeptide
* p \ 0.05 compared to baseline
Time (Months)


















Fig. 2 Change in visual analogue scale pain scores (VAS) in patients
with osteonecrosis of the knee treated with bisphosphonates
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Radiological findings
In all patients, the initial MRI scan showed typical
appearance for ON with subchondral area of low signal and
signal alteration indicative of perifocal bone oedema (low
signal intensity on T1-weighted images corresponding
to areas of high signal intensity on fat-suppressed T2-
weighted images). At the follow-up MRI after 2–3 months
of treatment bone marrow oedema resolved completely in
18 patients (out of 27), in the remaining substantial
reduction in bone oedema could be observed. The oste-
onecrotic area resolved completely in five patients; in the
others, there was demarcation with sclerotic changes of the
necrotic area. No further collapse of articular surface
occurred during the whole observation period.
Tolarability and side effects
In general, bisphosphonate treatment was well tolerated.
Four patients experienced an acute phase reaction after IV
pamidronate with arthralgias and myalgias. The symptoms,
however, were moderate and the treatment course could be
completed in all patients. Oral treatment with alendronate
was tolerated without side effects in all patients.
Discussion
The most important finding of the present study was the
rapid and sustained improvement in clinical symptoms and
disability, as well as resolution of the bone marrow oedema
indicating a possible beneficial effect of bisphosphonates in
patients with osteonecrosis. Specifically, pain reduction
(assessed by the VAS) of 30% after 4–6 weeks and of 80%
after 6 months during bisphosphonate therapy could be
observed. Complete or partial resolution of bone marrow
oedema was documented in all cases. The size of the
osteonecrotic area did not change significantly during the
short observation period. However, in early stages of ON,
complete resolution and in more advanced stages, demar-
cation of the osteonecrotic area was observed.
The development of osteonecrosis following arthro-
scopic knee-surgery is a rare event. In a series of publi-
cations, a total of 49 cases have been reported [6, 10, 12,
13, 20, 23, 26, 35, 39, 42, 46]. In 21 patients, in which
treatment outcome has been reported surgical reinter-
vention (9 alloarthroplasties, 1 tibial osteotomy, 1 core
decompression) was needed in eleven patients. Only in five
cases a favourable outcome on conservative treatment
(mechanical unloading, anti-inflammatory drugs) could be
observed. From these observations one might conclude that
favourable treatment response on non-invasive treatment is
limited.
Prognosis appears to be unfavourable in postarthro-
scopic ON, with progression to irreversible stages in most
cases [39]. Reasons for the poor outcome could be
delayed diagnosis and treatment because of existing
degenerative changes before the arthroscopic intervention.
Treatment options of ON depend in general on the size of
the lesion, smaller lesion being managed by mechanical
unloading, insole with lateral wedge and use of non-ste-
roidal anti-inflammatory drugs [39]. Larger lesions ([50%
of the femoral condyle or [5 cm2) in general require
osteotomy or arthroplasty[31]. In early stages, treatment
with core decompression of the bone has been success-
fully used [11, 19, 33]. Some authors report medical
therapy with Iloprost, a prostacyclin analogue, which has
been used in patients with bone marrow oedema and
osteonecrosis, and in children with aseptic osteonecrosis
of the proximal femur [5, 16, 41]. In these patients,
treatment with Iloprost resulted in resolution of pain and
rapid regression of the bone marrow oedema and sub-
chondral lesions on MRI. In regard of the unfavourable
prognosis and the limited non-surgical treatment possi-
bility, other treatment possibilities are warranted in
avoiding the need for arthroplasty.
In experimental animal studies, it has been shown that
alendronate and more recently zoledronate treatment pre-
vents resorption of necrotic bone during revascularization
[8, 9]. There are several reports of successful bisphosph-
onate treatment of the transient osteoporosis of the hip or
osteonecrosis of the femoral head [1, 2, 14, 29, 36, 37, 43,
50]. In an uncontrolled clinical study, 16 patients with
avascular necrosis of the hip were treated with alendronate
and an improvement in pain, disability and function com-
pared to the expected natural history of the disease was
found [3]. In a recently published observation from the
same authors of 395 hips with avascular necrosis which
were treated with alendronate for 3 years with a mean
follow-up of 4 years improvement in the clinical function,
a reduction in the rate of collapse and a decrease in the
requirement for total hip replacement, compared with the
findings of other studies in which no treatment was given
[2]. In one of the few randomized controlled trial with
alendronate treatment in 40 patients with atraumatic oste-
onecrosis of the femoral head with an involvement of at
least 30% of the head, only one patient in the alendronate
group needed a total hip arthroplasty whereas 16 subjects
in the control group underwent total hip arthroplasty over
an observation period of 28 months [29]. Thus, Alendro-
nate treatment was effective in preventing early collapse of
the femoral head in these patients. In another study using
intravenous ibandronate in the treatment of transient oste-
oporosis of the hip, it has been shown that bone marrow
oedema resolved completely in the MRI, and a significant
pain relief could be observed [44].
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In accordance with the findings in patients with avas-
cular necrosis of the hip, bisphosphonates appear to be also
beneficial in patients with osteonecrosis of the knee. The
optimal dosage and duration of the bisphosphonate treat-
ment in ON of the knee is not known. The dosage regimen
used in the present study was chosen based on animal data
which have shown that the prevention of resorption of
necrotic bone during revascularisation is dose-dependent
[8, 48]. Nevertheless, this study would support the use of
bisphosphonates for the treatment of osteonecrosis and
bone marrow oedema of the knee.
There are limitations in this study. First, the number of
patients included in the present study is rather small,
nevertheless significant reduction in pain score could be
detected early after initiation of bisphosphonate therapy.
Secondly, the lack of a control group does not allow
comparing definitively beneficial effects of bisphospho-
nates against the natural course of disease. And thirdly, the
follow-up period was only 6–12 months, which may have
been too short to demonstrate treatment failure.
Conclusion
In conclusion, bisphosphonate treatment of osteonecrosis
of the knee was associated with a rapid improvement of the
clinical symptoms and disability. Also complete or partial
resolution of bone marrow oedema and demarcation or
resolution of the osteonecrotic area in MRI could be
observed. A preventive effect against progressive destruc-
tion of the architecture of the knee following spontaneous
and postarthroscopic osteonecrosis can be assumed. Fur-
ther randomized, controlled trials are needed to confirm a
beneficial effect of bisphosphonate therapy in osteonecrosis
of the knee.
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